Nxera Pharma to Receive $8.6M Milestone Payment from Centessa for OX2R Development
Tokyo, Japan and Cambridge, UK, September 3, 2026 Nxera Pharma announced that Centessa Pharmaceuticals, a wholly owned subsidiary of...
neurological disorders
Advertisement
AAN, AHS Update Migraine Prevention Medication Guidelines
MINNEAPOLIS, Minnesota, Aug. 31, 2026 The American Academy of Neurology (AAN) and the American Headache Society (AHS) have issued...
Splash Beverage Acquires Global Rights to CannEpil Therapy
FORT LAUDERDALE, Fla., July 7, 2026 Splash Beverage Group, Inc. has announced the acquisition of exclusive global licensing rights...
APDA Launches Mental Health Training for Parkinson’s Care
NEW YORK, July 7, 2026 The American Parkinson Disease Association (APDA) has announced the launch of “Bridging Mental Health...
Merz Therapeutics and Teijin Secure Japan Approval for XEOMIN®
TOKYO, Japan and FRANKFURT, Germany, June 19, 2026 Teijin Pharma Limited and Merz Therapeutics GmbH have announced that Japan’s...
Advertisements
SK Life Science NDA for Cenobamate Suspension Accepted
PARAMUS, N.J., June 15, 2026 SK Life Science, Inc. has announced that the U.S. Food and Drug Administration (FDA)...
Servier Acquires Edgewise Muscular Dystrophy Business for $2.65B
SURESNES, France, June 1, 2026 Servier has announced a landmark agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in...
AbbVie Secures EU Approval for AQUIPTA as Acute Migraine Treatment
NORTH CHICAGO, Ill., June 2, 2026 AbbVie has announced that the European Commission (EC) has approved AQUIPTA® (atogepant) for...
Resmed Completes Noctrix Health Acquisition to Expand Sleep Care
SAN DIEGO, June 1, 2026 Resmed has completed its acquisition of Noctrix Health, significantly expanding its clinical sleep health...
IDEAYA and Servier Report Breakthrough mUM Phase 3 Data
SOUTH SAN FRANCISCO, Calif., June 1, 2026 IDEAYA Biosciences and Servier have unveiled compelling results from the registrational Phase...
Advertisement
